Literature DB >> 30019835

Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index.

Elliot B Tapper1,2, Monica Konerman1, Susan Murphy3,4, Christopher J Sonnenday5.   

Abstract

Frailty is increasingly recognized as a predictor of poor outcomes in solid organ transplantation. The most widely utilized frailty tool, the Fried Frailty Index (FFI), includes patient-reported exhaustion, weight loss, and physical activity as well as measured walk speed and handgrip. Although hepatic encephalopathy (HE) is common among liver transplant candidates, data are lacking regarding its impact on the interpretation of frailty. We prospectively enrolled 685 patients with cirrhosis during their transplant evaluation, following them until death or transplantation. Our cohort was aged 54.5 ± 10.3 years, 60% male, with an average MELD score of 14.7 ± 6.3. A history of HE was present in 39%. Frailty was present in 41%, associated with higher MELD, low albumin, ascites, and HE. HE was associated with frail performance on three components of the FFI-grip (odds ratio 1.41 95% CI, 1.03-1.92), walk speed (1.56 95% CI, 1.14-2.15), and decreased energy (1.44 95% CI, 1.05-1.99). These three components were associated with transplant free survival in the whole cohort: energy (hazard ratio 1.67 95% CI, 1.25-2.28), grip (1.63 95% CI, 1.24-2.16), and walk speed (1.56 95% CI, 1.19-2.04). However, among patients with HE, the FFI was not associated with survival. HE plays a critical role in the frailty phenotype and the implications of frailty among patients with cirrhosis evaluated for liver transplantation.
© 2018 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  cirrhosis; clinical research/practice; health services and outcomes research; liver transplantation/hepatology; patient survival

Year:  2018        PMID: 30019835      PMCID: PMC6166663          DOI: 10.1111/ajt.15020

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  25 in total

1.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

2.  Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation.

Authors:  Jennifer C Lai; Kenneth E Covinsky; Hilary Hayssen; Blanca Lizaola; Jennifer L Dodge; John P Roberts; Norah A Terrault; Sandy Feng
Journal:  Liver Int       Date:  2015-02-12       Impact factor: 5.828

3.  Validation of EncephalApp, Smartphone-Based Stroop Test, for the Diagnosis of Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Richard K Sterling; Arun J Sanyal; Muhammad Siddiqui; Scott Matherly; Velimir Luketic; R Todd Stravitz; Michael Fuchs; Leroy R Thacker; HoChong Gilles; Melanie B White; Ariel Unser; James Hovermale; Edith Gavis; Nicole A Noble; James B Wade
Journal:  Clin Gastroenterol Hepatol       Date:  2014-05-17       Impact factor: 11.382

4.  Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver.

Authors:  Hendrik Vilstrup; Piero Amodio; Jasmohan Bajaj; Juan Cordoba; Peter Ferenci; Kevin D Mullen; Karin Weissenborn; Philip Wong
Journal:  Hepatology       Date:  2014-07-08       Impact factor: 17.425

5.  Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value.

Authors:  Puneeta Tandon; Michael Ney; Ivana Irwin; Mang M Ma; Leah Gramlich; Vincent G Bain; Nina Esfandiari; Vickie Baracos; Aldo J Montano-Loza; Robert P Myers
Journal:  Liver Transpl       Date:  2012-10       Impact factor: 5.799

6.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

7.  Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests.

Authors:  Elliot B Tapper; Neehar D Parikh; Akbar K Waljee; Michael Volk; Noelle E Carlozzi; Anna S-F Lok
Journal:  Am J Gastroenterol       Date:  2018-03-13       Impact factor: 10.864

8.  Depression and Frailty in Patients With End-Stage Liver Disease Referred for Transplant Evaluation.

Authors:  D C Cron; J F Friedman; G S Winder; A E Thelen; J E Derck; J W Fakhoury; A D Gerebics; M J Englesbe; C J Sonnenday
Journal:  Am J Transplant       Date:  2016-02-24       Impact factor: 8.086

9.  Diagnosis of covert hepatic encephalopathy without specialized tests.

Authors:  Eiman Nabi; Leroy R Thacker; James B Wade; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Douglas M Heuman; Iliana Bouneva; Arun J Sanyal; Mohammad S Siddiqui; Velimir Luketic; Melanie B White; Pamela Monteith; Nicole A Noble; Ariel Unser; Jasmohan S Bajaj
Journal:  Clin Gastroenterol Hepatol       Date:  2013-12-19       Impact factor: 11.382

10.  Analytic morphomics, core muscle size, and surgical outcomes.

Authors:  Michael J Englesbe; Jay S Lee; Kevin He; Ludi Fan; Douglas E Schaubel; Kyle H Sheetz; Calista M Harbaugh; Sven A Holcombe; Darrel A Campbell; Christopher J Sonnenday; Stewart C Wang
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

View more
  19 in total

1.  Neurocognitive and Muscular Capacities Are Associated with Frailty in Adults with Cirrhosis.

Authors:  Susan L Murphy; James K Richardson; Jennifer Blackwood; Beanna Martinez; Elliot B Tapper
Journal:  Dig Dis Sci       Date:  2020-01-25       Impact factor: 3.199

Review 2.  Frailty Assessment in Patients with Liver Cirrhosis.

Authors:  Amanda C Van Jacobs
Journal:  Clin Liver Dis (Hoboken)       Date:  2019-10-09

3.  Frailty in liver transplantation: An expert opinion statement from the American Society of Transplantation Liver and Intestinal Community of Practice.

Authors:  Jennifer C Lai; Christopher J Sonnenday; Elliot B Tapper; Andres Duarte-Rojo; Michael A Dunn; William Bernal; Elizabeth J Carey; Srinivasan Dasarathy; Binita M Kamath; Matthew R Kappus; Aldo J Montano-Loza; Shunji Nagai; Puneeta Tandon
Journal:  Am J Transplant       Date:  2019-05-08       Impact factor: 8.086

4.  Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study.

Authors:  Manaav Mehta; Jeremy Louissaint; Neal S Parikh; Michelle T Long; Elliot B Tapper
Journal:  Am J Med       Date:  2021-08-28       Impact factor: 4.965

5.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

6.  Frailty and Outcomes After Liver Transplantation.

Authors:  Elliot B Tapper
Journal:  Curr Transplant Rep       Date:  2019-01-14

7.  Patient Frailty Is Independently Associated With the Risk of Hospitalization for Acute-on-Chronic Liver Failure.

Authors:  Shivani Shah; David S Goldberg; David E Kaplan; Vinay Sundaram; Tamar H Taddei; Nadim Mahmud
Journal:  Liver Transpl       Date:  2020-10-28       Impact factor: 5.799

8.  Applying Administrative Data-Based Coding Algorithms for Frailty in Patients With Cirrhosis.

Authors:  Jeremy Louissaint; Susan L Murphy; Christopher J Sonnenday; Anna S Lok; Elliot B Tapper
Journal:  Liver Transpl       Date:  2021-07-31       Impact factor: 5.799

Review 9.  Assessment of the Frail Patient With End-Stage Liver Disease: A Practical Overview of Sarcopenia, Physical Function, and Disability.

Authors:  Felicity R Williams; Don Milliken; Jennifer C Lai; Matthew J Armstrong
Journal:  Hepatol Commun       Date:  2021-02-26

10.  The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis.

Authors:  Zachary M Saleh; Quintin P Solano; Jeremy Louissaint; Peter Jepsen; Elliot B Tapper
Journal:  United European Gastroenterol J       Date:  2021-06-08       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.